<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>328-MARAVIROC.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MARAVIROC" rxcui="620216">
<ATC code="J05AX09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FOSAMPRENAVIR" rxcui="358262">
<ATC code="J05AE07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Significant decrease of the concentrations of amprenavir that could lead to a loss of the virological response</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>328-MARAVIROC.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MARAVIROC" rxcui="620216">
<ATC code="J05AX09" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>In the absence of the administration at the same time with a strong inhibitor of CYP3A4, decrease of the concentrations of maraviroc by the inducer</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>The dose of maraviroc must be increased to 600 mg twice a day in this situation. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>328-MARAVIROC.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MARAVIROC" rxcui="620216">
<ATC code="J05AX09" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the concentrations of maraviroc by the inhibitor</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>The dose of maraviroc must be reduced to 150 mg twice a day if it is taken with this inhibitor.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>328-MARAVIROC.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MARAVIROC" rxcui="620216">
<ATC code="J05AX09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of maraviroc that could lead to a loss of the virological response</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
</INTERACTIONS>
